Roni Bitterman

Colistin alone versus colistin plus meropenem for treatment of severe infections caused by carbapenem-resistant Gram-negative bacteria: an open-label, randomised controlled trial

Mical Paul, George L. Daikos, Emanuele Durante‐Mangoni et al. · The Lancet Infectious Diseases · 2018 · 624 citations

Life Sciences, Infectious Diseases, Microbiology +14

Seven Versus 14 Days of Antibiotic Therapy for Uncomplicated Gram-negative Bacteremia: A Noninferiority Randomized Controlled Trial

Dafna Yahav, Erica Franceschini, Fidi Koppel et al. · Clinical Infectious Diseases · 2018 · 412 citations · Full text

Pharmacy, Infectious Diseases, Internal Medicine +13

Treatment Outcomes of Colistin- and Carbapenem-resistant Acinetobacter baumannii Infections: An Exploratory Subgroup Analysis of a Randomized Clinical Trial

Yaakov Dickstein, Jonathan Lellouche, Maayan Ben Dalak Amar et al. · Clinical Infectious Diseases · 2018 · 126 citations

Life Sciences, Infectious Diseases, Microbiology +17

Colistin plus meropenem for carbapenem-resistant Gram-negative infections: in vitro synergism is not associated with better clinical outcomes

Amir Nutman, Jonathan Lellouche, Elizabeth Temkin et al. · Clinical Microbiology and Infection · 2020 · 78 citations

Life Sciences, Infectious Diseases, Pharmacology +16

The Association Between Empirical Antibiotic Treatment and Mortality in Severe Infections Caused by Carbapenem-resistant Gram-negative Bacteria: A Prospective Study

Yael Zak-Doron, Yael Dishon Benattar, Iris Pfeffer et al. · Clinical Infectious Diseases · 2018 · 45 citations

Pharmacy, Infectious Diseases, Microbiology +17